The efficacy and the safety of eltrombopag in pediatric patients with severe aplastic anemia: a systematic review
BackgroundAcquired aplastic anemia (AAA) in pediatric patients is a rare disorder characterized by hypocellular bone marrow and pancytopenia. Eltrombopag, an oral thrombopoietin receptor agonist, provides a hematologic improvement in adults with severe aplastic anemia (SAA) refractory to immunosuppr...
Saved in:
Main Authors: | Maria Maddalena Marrapodi (Author), Annamaria Mascolo (Author), Domenico Roberti (Author), Martina Di Martino (Author), Concetta Rafaniello (Author), Consiglia Riccardi (Author), Francesca Rossi (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2023-04-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Role of eltrombopag in severe aplastic anemia treatment in children
by: Min-Yu Su, et al.
Published: (2021) -
Aplastic Anemia Treated with Eltrombopag during Pregnancy
by: Yuri Suminaga, et al.
Published: (2022) -
Eltrombopag for the treatment of aplastic anemia: current perspectives
by: Lum SH, et al.
Published: (2016) -
Quinolones-Induced Musculoskeletal, Neurological, and Psychiatric ADRs: A Pharmacovigilance Study Based on Data From the Italian Spontaneous Reporting System
by: Cristina Scavone, et al.
Published: (2020) -
The safety of blinatumomab in pediatric patients with acute lymphoblastic leukemia: A systematic review and meta-analysis
by: Maria Maddalena Marrapodi, et al.
Published: (2022)